IN8bio reports Q2 2026 results, GBM survival data and TCE platform progress
The company disclosed median overall survival exceeding 19.5 months in glioblastoma patients treated with repeat-dosed DeltEx DRI, alongside $18.0 million in cash as of June 30, 2026.
SEC filing